Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 335 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | September 04, 2015

PCSK9 Drugs Are Here (and Way Over There)

As the first generation of the cholesterol-lowering drugs hits the market, investors should already be looking at the next-generation products.

Investing | August 21, 2015

3 Low-Price Biotech Stocks That Could Pop or Drop in 2016

Agenus Inc., Array BioPharma, and Idera Pharmaceuticals are expecting to release data from cancer drug trials in the coming year.

Investing | July 18, 2015

These 2 Stocks Doubled in 2015 -- Is 1 Still a Buy?

Advaxis and Agenus have been two of the best performing stocks of 2015. Can they continue to crush the broader markets or is it time to take profits?

Investing | July 14, 2015

Midyear Report Card: Grading My Biotech Predictions for 2015

One Foolish investor shines a bright light on his biotech stocks predictions for this year.

Investing | June 27, 2015

Is it Time for this Biotech to Change Management?

With Aegerion Pharmaceuticals down 500% from its all-time high, the current CEO's tenure is trying investors' patience.

Investing | June 11, 2015

3 Things AbbVie Inc.'s Management Wants You to Know

AbbVie's management team had a lot to talk about on their last investor conference call. Here are my three takeaways you need to know when considering the stock for investment.

Investing | June 10, 2015

Cancer Stocks: 2 to Sell, 1 to Buy

Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.

Investing | June 10, 2015

Cancer Stocks: 2 to Sell, 1 to Buy

Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.

Investing | June 07, 2015

Cancer Drugs: 2 Stocks to Watch

AstraZeneca and Agenus Inc. are paving the way for a new generation of breakthrough cancer drugs that boost the immune system's ability to detect and eradicate malignancies. Here's what investors need to know about these two biopharmas going forward.

Investing | May 31, 2015

Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences, Inc.

AbbVie and Gilead are often compared because of their competing hepatitis C drugs. These two biopharmas nevertheless have fundamentally different core areas of expertise and approaches to drug development. And these differences give AbbVie a better long-term outlook than Gilead.

Results 1 - 10 of 335 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology